pharmaphorum16h
How pharma is tackling new direct-to-patient programmes
In some ways, pharma connecting directly with patients isn’t novel at all: pharma companies in the United States have been ...
pharmaphorum18h
Harnessing zero‑party data: Transforming pharma advertising for better patient engagement
This kind of voluntary information that customers share directly with advertisers is known as zero-party data – and it has ...
pharmaphorum18h
Direct-to-patient is more than just telehealth – with EVERSANA’s Faruk Abdullah
The idea of direct-to-patient channels in pharma conjures up services like Lilly Direct and PfizerForAll. But ...
pharmaphorum22h
AZ grabs pair of EU approvals for top cancer drugs
Daiichi Sankyo-partnered anti-HER2 drug Enhertu (trastuzumab deruxtecan) has been cleared by the European Commission for use ...
pharmaphorum20h
MoonLake secures $500m for lead drug, plus other financings
MoonLake Immunotherapeutics has secured up to $500 million in non-dilutive financing from Hercules Capital, bolstering its ...
pharmaphorum22h
Lilly throws lifeline to Sangamo with $1.4bn licensing deal
Lilly is the third company to partner with Sangamo on STAC-BBB after Astellas Gene Therapies, which paid $20 million upfront ...
pharmaphorum19h
Paige's cancer detection AI gets FDA breakthrough status
Digital pathology specialist Paige has been awarded breakthrough device status from the FDA for an artificial intelligence ...
pharmaphorum23h
Uplizna is first drug FDA-cleared for rare disease IgG4-RD
Acquired as part of its $27.8 billion takeover of Horizon Therapeutics in 2023, CD19-targeting Uplizna (inebilizumab) is the ...